Bringing the fundamentals into focus…
Back to enGene Therapeutics Inc.
How enGene Therapeutics Inc. stacks up
ENGN · against 103 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #45 of 104 · scores higher than 39% of peers
Bars: peers in each 10-point band of the valuation score32 peers with a valuation score of 30–39, including ENGN · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -120.1% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -95.8% vs peer median 0.0%
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
Metric by metric
Position: dot = ENGN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ENGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 88 reported | -130.9% | -14.6% | 9% | 30% | |
| EBITDA yieldHigher is better · 112 reported | 169.6% | -2.9% | 95% | 50% | |
| Free cash flow yieldHigher is better · 78 reported | -95.8% | -15.8% | 6% | 20% | |
| Book yieldHigher is better · 93 reported | 212.1% | 75.1% | 88% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ENGN| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 45 | 186M USD | 33 | 43 | |
| 45 | 100M USD | 33 | 37 | |
| 45 | 110M USD | 33 | 38 | |
| 45 | 213M USD | 33 | ||
| 45 | 109M USD | 33 | 47 | |
| 45 | 216M USD | 33 | 44 | |
| 45 | 126M USD | 33 | 32 | |
| 45 | 215M USD | 33 | 34 | |
| 45 | 110M USD | 33 | 54 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score